These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 15077872

  • 1. Therapy of IgA nephropathy with mycophenolate mofetil--report of 3 cases.
    Bergner R, Hoffmann M, Brass H, Uppenkamp M.
    Clin Nephrol; 2004 Mar; 61(3):207-12. PubMed ID: 15077872
    [Abstract] [Full Text] [Related]

  • 2. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
    Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J, Carter B, Jung B, Hernandez G, Gipson D, Wyatt RJ.
    Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
    [Abstract] [Full Text] [Related]

  • 3. Mycophenolate mofetil in primary glomerulopathies.
    Sepe V, Libetta C, Giuliano MG, Adamo G, Dal Canton A.
    Kidney Int; 2008 Jan; 73(2):154-62. PubMed ID: 17989649
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
    Hou JH, Le WB, Chen N, Wang WM, Liu ZS, Liu D, Chen JH, Tian J, Fu P, Hu ZX, Zeng CH, Liang SS, Zhou ML, Zhang HT, Liu ZH.
    Am J Kidney Dis; 2017 Jun; 69(6):788-795. PubMed ID: 28215945
    [Abstract] [Full Text] [Related]

  • 5. Mycophenolate Mofetil: A Possible Alternative Treatment for IgA Nephropathy.
    Baraldi O, Comai G, Cuna V, Cappuccilli M, Serra C, Ronco C, La Manna G.
    Contrib Nephrol; 2017 Jun; 190():108-116. PubMed ID: 28535523
    [Abstract] [Full Text] [Related]

  • 6. Mycophenolate mofetil treatment of crescentic Henoch-Schönlein nephritis with IgA depositions.
    Dede F, Onec B, Ayli D, Gonul II, Onec K.
    Scand J Urol Nephrol; 2008 Jun; 42(2):178-80. PubMed ID: 17853044
    [Abstract] [Full Text] [Related]

  • 7. Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil.
    Chandrakantan A, Ratanapanichkich P, Said M, Barker CV, Julian BA.
    Nephrol Dial Transplant; 2005 Jun; 20(6):1214-21. PubMed ID: 15797890
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Retrospective study of mycophenolate mofetil treatment in IgA nephropathy with proliferative pathological phenotype.
    Liang Y, Zhang J, Liu D, Quan S, Xing G, Liu Z.
    Chin Med J (Engl); 2014 Jun; 127(1):102-8. PubMed ID: 24384432
    [Abstract] [Full Text] [Related]

  • 10. Treatment and outcome of IgA nephropathy in children from one single center experience.
    Mao Y, Zhou W, Zhou Z, Zhang C, Shen J, Yin L.
    BMC Pediatr; 2023 Jul 26; 23(1):377. PubMed ID: 37495962
    [Abstract] [Full Text] [Related]

  • 11. [A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy].
    Chen X, Chen P, Cai G, Wu J, Cui Y, Zhang Y, Liu S, Tang L.
    Zhonghua Yi Xue Za Zhi; 2002 Jun 25; 82(12):796-801. PubMed ID: 12126522
    [Abstract] [Full Text] [Related]

  • 12. [Mycophenolate mofetil in high risk IgA glomerulonephritis].
    Frutos MA, López V, Alférez MJ, Aranda P.
    Nefrologia; 2005 Jun 25; 25(4):387-92. PubMed ID: 16231504
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Meta-analysis of mycophenolate mofetil in IgA nephropathy.
    Navaneethan SD, Viswanathan G, Strippoli GF.
    Nephrology (Carlton); 2008 Feb 25; 13(1):90. PubMed ID: 18199113
    [No Abstract] [Full Text] [Related]

  • 15. Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy.
    Lv J, Zhang H, Cui Z, Su T, Zhang Y, Wang H.
    Nephrol Dial Transplant; 2008 Sep 25; 23(9):2868-72. PubMed ID: 18463325
    [Abstract] [Full Text] [Related]

  • 16. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study.
    Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF.
    Kidney Int; 2004 May 25; 65(5):1842-9. PubMed ID: 15086925
    [Abstract] [Full Text] [Related]

  • 17. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies.
    Sahin GM, Sahin S, Kantarci G, Ergin H.
    Nephrology (Carlton); 2007 Jun 25; 12(3):285-8. PubMed ID: 17498124
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review.
    Chen Y, Li Y, Yang S, Li Y, Liang M.
    BMC Nephrol; 2014 Dec 05; 15():193. PubMed ID: 25475967
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of mycophenolate mofetil in the treatment for IgA nephropathy: a meta-analysis of randomized controlled trials.
    Peng XJ, Zheng WM, Fu R, Huang YH, Deng MH, Tao SS, Wang TJ, Zhu C.
    Clin Exp Nephrol; 2021 Jul 05; 25(7):788-801. PubMed ID: 33710500
    [Abstract] [Full Text] [Related]

  • 20. Long-term study of mycophenolate mofetil treatment in IgA nephropathy.
    Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN.
    Kidney Int; 2010 Mar 05; 77(6):543-9. PubMed ID: 20032964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.